SAN FRANCISCO, March 9 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will host a teleconference and webcast with management to discuss fourth quarter and year-end 2008 financial results and provide a general business update on Monday, March 16, 2009, at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended December 31, 2008 will be released after markets close on March 16, 2009.
Interested parties may call 877-718-5104 from the U.S. or +1-719-325-4794 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company’s website for 30 days.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer’s and Huntington’s diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer’s disease. The program also includes additional trials planned to begin this year in Alzheimer’s disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington’s disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,
+1-415-829-4101; or Daryl Messinger of WeissComm Partners, +1-415-946-1062,
for Medivation, Inc.
Web site: http://www.medivation.com/
